검색어: bcrp (영어 - 슬로베니아어)

bcrp substrates
substrati bcrp

mechanism: bcrp
mehanizem:

(bcrp inhibition)
(inhibicija bcrp)

interactions with bcrp
medsebojno delovanje z bcrp

(intestinal bcrp inhibition)
(zaviranje črevesne bcrp)

bcrp, mrp2, oat3 and oct1 substrates
substrati bcrp, mrp2, oat3 in oct1

medicinal products transported by bcrp
zdravila, ki jih prenaša bcrp

(inhibition of oatp1b and bcrp)
(zaviranje prenašalcev oatp1b in bcrp)

(cyp3a4/5 or bcrp inhibition)
(inhibicija cyp3a4/5 ali bcrp)

(primarily due to intestinal bcrp inhibition
(predvsem zaradi zaviranja črevesne bcrp

dasabuvir is an inhibitor of bcrp in vivo.
dasabuvir zavira bcrp in vivo.

(inhibition of drug transporters oatp and bcrp)
(zaviranje prenašalcev oatp in bcrp)

(oatp1b1/3, bcrp transporter inhibition)
(močno zaviranje cyp3a4)

bcrp, oatp1b1, oatp1b3 and p-gp substrates
substrati bcrp, oatp1b1, oatp1b3 in p-gp

metabolite m-5 is a weak bcrp-substrate.
presnovek m-5 je šibek substrat bcrp.

lapatinib is a substrate for the transport proteins pgp and bcrp.
lapatinib je substrat za transportna proteina pgp in bcrp.

lapatinib inhibits the transport proteins bcrp and oatp1b1 in vitro.
lapatinib in vitro zavira transportne proteine bcrp in oatp1b1.

caution is advised when cresemba is given concomitantly with substrates of bcrp.
pri sočasni uporabi zdravila cresemba s substrati bcrp je potrebna previdnost.

lapatinib inhibits the transport proteins pgp, bcrp and oatp1b1 in vitro.
lapatinib in vitro zavira transportne proteine pgp, bcrp in oatp1b1.

based on in vitro studies, osimertinib is a competitive inhibitor of bcrp transporters.
na podlagi študij in vitro je osimertinib kompetitivni zaviralec prenašalcev bcrp.